SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesMetabolicSemaglutide

Semaglutide

/ Long-acting GLP-1 receptor agonist
TIER 1 · ClinicalN = 0 · TESTING PENDINGMW 4113.58 g·mol⁻¹LAST REVIEW 2026·04·20

ALIAS · Ozempic · Wegovy · Rybelsus

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · 4113.58CLASS · Long-acting GLP-1 receptor agonistCATEGORY · Metabolic

FDA-approved for type 2 diabetes (2017), chronic weight management (2021), cardiovascular risk reduction in obesity (2024), and diabetic kidney disease (2025).

§ B · Mechanism of action

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a modified human GLP-1 analog with an Aib substitution at position 8 (resisting DPP-4 cleavage) and a C18 fatty-diacid side chain at Lys26 that drives albumin binding and extends plasma half-life to approximately 165 hours.

Activation of pancreatic beta-cell GLP-1 receptors enhances glucose-dependent insulin secretion and suppresses glucagon. Hypothalamic and brainstem GLP-1 receptors slow gastric emptying and increase satiety. Unlike tirzepatide, semaglutide is a pure GLP-1R mono-agonist with no meaningful GIP activity.

§ C · Human clinical evidence

Extensive. Multiple large phase-3 randomized controlled trials support approvals for type 2 diabetes (SUSTAIN program), chronic weight management (STEP program), cardiovascular risk reduction in obesity without diabetes (SELECT), and diabetic kidney disease (FLOW).

§ D · Primary literature
PubMed33567185Wilding JPH et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity · New England Journal of Medicine · human-phase-3-rctMean weight change of -14.9% with semaglutide 2.4 mg vs -2.4% with placebo over 68 weeks. 86.4% achieved ≥5% weight loss vs 31.5% placebo.Limitations: Conducted in adults without diabetes; excludes pediatrics and populations with major comorbidities.2021
PubMed37952131Lincoff AM et al.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · New England Journal of Medicine · human-phase-3-rctHR for major adverse cardiovascular events 0.80 (95% CI 0.72-0.90, p<0.001) with semaglutide 2.4 mg vs placebo. Basis for 2024 Wegovy cardiovascular indication.Limitations: Population had established cardiovascular disease and overweight/obesity without diabetes; generalizability to other populations remains to be established.2023
PubMed27633186Marso SP et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes · New England Journal of Medicine · human-phase-3-rctHR for major adverse cardiovascular events 0.74 (95% CI 0.58-0.95) with semaglutide vs placebo in type 2 diabetes. Retinopathy complications signal HR 1.76.Limitations: Cardiovascular safety trial design; not powered for individual MACE components. Retinopathy signal requires ongoing monitoring.2016
PubMed38785209Perkovic V et al.Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · New England Journal of Medicine · human-phase-3-rctHR for composite kidney endpoint 0.76 (95% CI 0.66-0.88). Trial stopped early for efficacy.Limitations: Population limited to type 2 diabetes with chronic kidney disease.2024
§ E · Dosage ranges studied

Factual reporting of what cited studies used — not a recommendation.

  • STEP 1 obesity phase-3 trial — Adult humans without diabetesTitrated to 2.4 mg Subcutaneous weeklyREFSTEP 1 (Wilding 2021)
  • SUSTAIN-6 T2DM cardiovascular outcomes trial — Adult humans with type 2 diabetes and established CV risk0.5 or 1.0 mg Subcutaneous weeklyREFSUSTAIN-6 (Marso 2016)
§ F · Safety signal

In pivotal trials the most common adverse events were gastrointestinal (nausea up to ~44% in STEP 1, diarrhea, vomiting, constipation) — generally mild to moderate and titration-related. Boxed warning for thyroid C-cell tumors based on rodent findings; human relevance is not established. Warnings in labeling include pancreatitis, gallbladder disease, acute kidney injury from dehydration, diabetic retinopathy complications (SUSTAIN-6 HR 1.76), and hypoglycemia when combined with insulin or sulfonylureas.

§ H · Regulatory status

Regulatory status

FDA status:
FDA-approved
Compounding:
Not eligible for compounding (approved, not in shortage)
§ I · Notable gaps and controversies

The FDA removed semaglutide from its drug shortage list in October 2024. As of 2026, compounding essentially-a-copy semaglutide is not permitted by 503A or 503B facilities absent a documented clinical difference for an individual patient. Salt forms such as semaglutide sodium were explicitly ruled out as valid APIs for compounding. FDA has issued multiple warning letters to online sellers marketing unapproved GLP-1 products.